Bim Biomarker-Guided Checkpoint Blockade Therapy for Metastasis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are inadequate in controlling or preventing metastasis, particularly in patients with elevated Bim levels, as they fail to effectively manage the interaction between PD-1 and B7-H1, leading to chronic engagement and T cell apoptosis.
Innovation Solution
Administering anti-B7-H1, anti-PD-1, or anti-CD80 antibodies or fusion proteins that interfere with the interaction between B7-H1 and PD-1 or CD80, reducing their engagement and thereby lowering Bim levels, which serves as a biomarker for determining the efficacy of checkpoint blockade therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint blockade therapy is administered to patients with elevated Bim levels, then anti-tumor immunity is enhanced, but T cell apoptosis increases due to chronic PD-1 engagement
Solution Approach 1:
The patent uses Bim protein levels as a feedback biomarker to monitor PD-1 engagement status. By measuring Bim levels in PD-1+ T cells, the system provides feedback on the extent of checkpoint blockade therapy engagement, allowing optimization of treatment to enhance anti-tumor immunity while minimizing T cell apoptosis
Solution Approach 2:
The patent identifies and measures changes in Bim protein levels as a parameter indicating the functional state of PD-1+ T cells. This parameter change serves as a biomarker to guide checkpoint blockade therapy, enabling differentiation between T cells with transient versus chronic PD-1 engagement
2Productivity
If current cancer treatments are used, then general cancer therapy is provided, but metastasis control and prevention are inadequate
Solution Approach 1:
The patent focuses on a specific subset of T cells (PD-1+ T cells with elevated Bim levels) that are particularly important for preventing metastasis. By targeting this specific population with checkpoint blockade therapy, the treatment achieves localized enhancement of anti-metastatic immunity rather than uniform treatment of all T cells
3Stability of the object's composition
If PD-1 and B7-H1 interaction is not blocked, then T cell activation is maintained, but chronic engagement leads to T cell death
Solution Approach 1:
The patent applies checkpoint blockade therapy selectively to patients and T cell populations where PD-1 engagement is chronically elevated (indicated by high Bim levels). This partial action approach blocks the harmful chronic engagement in specific cases while avoiding unnecessary intervention in T cells with transient, physiological PD-1 activation
Data Source
AI summary
Materials and methods for treating cancer, including materials and methods for treating cancer in patients identified as having elevated levels of Bim.